Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
Provided By GlobeNewswire
Last update: May 27, 2025
Cash runway extended into 2028; capital proceeds to fund operations through potential 2027 efficacy readout for LX2006 in Friedreich ataxia cardiomyopathy
Financing led by Frazier Life Sciences and Janus Henderson Investors with participation from new and existing investors
Read more at globenewswire.com
